IRVINE, CA / ACCESS Newswire / October 29, 2026 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2027 first quarter ended September 30, 2026. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2027 with the Securities and Exchange Commission today.

Quarter Ended September 30, 2026

Net sales for the three months ended September 30, 2026, increased $2.1 million, or 11%, to $20.6 million from $18.5 million for the three months ended September 30, 2025. The increase is driven primarily by a $3.3 million increase in medical device revenue, inclusive of rebates, of which $1.8 million relates to the next-generation handpiece we sell to our largest customer, offset by a $1.7 million decrease in repairs of the legacy handpiece we sell to that customer, coupled with an increase in revenue of $511,000 generated by the Company’s newly acquired subsidiary, Advanced Precision Machining, LLC (“APM”), exclusive of inter-company sales in the amount of $814,000 which are eliminated in consolidation.

Gross profit for the three months ended September 30, 2026, increased $1.5 million, or 28%, compared to the year-ago period. Gross margin increased by 4 percentage points to 33% during the three months ended September 30, 2026, compared to 29% during the corresponding year-ago period, due primarily as a result of favorable product mix.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended September 30, 2026, increased $1.1 million, or 48%, to $3.3 million compared to $2.3 million for the prior fiscal year’s corresponding quarter. The increase relates to a $442,000 increase in engineering and a $642,000 increase in selling, general and administrative expenses. The increase in engineering relates to personnel costs as well as higher internal project expenditures. The increase in selling, general and administrative expense is primarily due to $466,000 of APM’s separate operations as well as $195,000 of higher personnel costs specifically related to accounting, mergers and acquisitions, human resources, and information technology.

Our operating income for the quarter ended September 30, 2026, increased $406,000, or 13%, to $3.5 million compared to $3.1 million for the prior fiscal year’s corresponding quarter. The increase reflects our increased gross profit, offset by our increased operating expenses, as described above.

Net income for the quarter ended September 30, 2026, decreased to $3.0 million, or $0.92 per diluted share, compared to net income of $4.7 million, or $1.40 per diluted share, for the quarter ended September 30, 2025. Our net income for the quarter ended September 30, 2026, contains unrealized gains on our marketable equity investments of $73,000, while our net income for the quarter ended September 30, 2025, includes unrealized gains on our marketable equity investments of $3.3 million. All of our investments are recorded at estimated fair value, and the period-to-period valuation can be highly volatile. For example, our investment in Monogram Technologies, Inc. was valued as of September 30, 2025 at the cash price we received in October 2025, upon its acquisition by Zimmer Biomet Holdings, Inc. We received $4.04 per share for each of the common shares we owned of Monogram, for a total of $8.9 million in cash proceeds.

CEO Comments

Richard L. (“Rick”) Van Kirk, the Company’s President and Chief Executive Officer, commented, “We are pleased with our first quarter results and continued top line revenue growth.” Mr. Van Kirk concluded, “We are also pleased to be working with the Monogram and Zimmer Biomet teams and expect to ship validation units later this fiscal year.”

About Pro-Dex, Inc.:

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adaptive torque-limiting technology and proprietary sealing solutions that appeal to our customers, primarily medical device distributors. Additionally, we provide engineering, quality, and regulatory consulting services to our customers. Our APM subsidiary manufactures parts and assemblies for the aerospace and defense industries in addition to providing several machined components to support Pro-Dex’s customers. Pro-Dex, Inc. also sells rotary air motors to a wide range of industries; however, these air motors comprise a de minimis portion of our business. Pro-Dex’s products are found in hospitals and medical engineering labs around the world. For more information, visit the Company’s websites at www.pro-dex.com and www.advanced-precision.com.

Statements herein concerning the Company’s plans, growth, and strategies may include ‘forward-looking statements’ within the context of the federal securities laws. Statements regarding the Company’s future events, developments, and future performance (including the expected shipment of Monogram validation units) as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company’s actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the risk factors and other disclosures concerning the operational and business concerns of the Company set forth in the Company’s filings with the Securities and Exchange Commission.

Contact:
Richard L. Van Kirk,
Chief Executive Officer
(949) 769-3200

(tables follow)

 

PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share amounts)

September 30,
2026
June 30,
2026
ASSETS
Current Assets:
Cash and cash equivalents
 $ 11,759 $ 8,192
Investments
 1,230 1,150
Accounts receivable, net of allowance for credit losses of $285 and $349 at September 30, 2026 and June 30, 2026, respectively
 17,507 21,205
Deferred costs
 27 70
Inventory
 21,899 21,458
Income taxes receivable
 1,081 620
Prepaid expenses and other current assets
 443 553
Total current assets
 53,946 53,248
Land and building, net
 5,944 5,967
Equipment and leasehold improvements, net
 5,359 5,373
Right-of-use asset, net
 2,048 602
Intangibles, net
 666 686
Deferred income taxes
 1,544 1,544
Investments
 497 504
Goodwill
 6,525 6,525
Other assets
 60 60
Total assets
 $ 76,589 $ 74,509
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable
 $ 5,321 $ 4,262
Accrued liabilities
 3,224 4,366
Income taxes payable
 124 124
Deferred revenue
 44 26
Notes payable.
 4,171 4,205
Total current liabilities
 12,884 12,983
Lease liabilities, net of current portion
 2,089 627
Notes payable, net of current portion
 12,270 13,266
Total non-current liabilities
 14,359 13,893
Total liabilities
 27,243 26,876
Shareholders’ Equity:
Common stock; no par value; 50,000,000 shares authorized; 3,203,334 and 3,186,135 shares issued and outstanding at September 30, 2026 and June 30, 2026, respectively
 – –
Retained earnings
 49,346 47,633
Total shareholders’ equity
 49,346 47,633
Total liabilities and shareholders’ equity
 $ 76,589 $ 74,509

PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share amounts)

 Three Months Ended September 30,
2026 2025
Net sales
 $ 20,560 $ 18,530
Cost of sales
 13,703 13,163
Gross profit
 6,857 5,367
Operating expenses:
Selling, general and administrative expenses
 2,132 1,490
Research and development costs
 1,210 768
Total operating expenses
 3,342 2,258
Operating income
 3,515 3,109
Other income (expense):
Interest and dividend income
 51 14
Unrealized gain on investments
 73 3,299
Interest expense
 (260 ) (200 )
Total other income (expense)
 (136 ) 3,113
Income before income taxes
 3,379 6,222
Provision for income taxes
 331 1,542
Net income
 $ 3,048 $ 4,680
Basic and diluted net income per share:
Basic net income per share
 $ 0.95 $ 1.43
Diluted net income per share
 $ 0.92 $ 1.40
Weighted-average common shares outstanding:
Basic
 3,206,304 3,261,753
Diluted
 3,315,415 3,338,805
Common shares outstanding
 3,203,334 3,262,004

SOURCE: Pro-Dex, Inc.

View the original press release on ACCESS Newswire

Media gallery

About The Author
Pro-Dex, Inc.